Zakaria Doughan

Zakaria Doughan

Auto-generated profile, based on publicly available information

Zakaria Doughan

Division of Maternal‐Fetal Medicine Department of Obstetrics Gynecology and Reproductive Sciences McGovern Medical School at UTHealth Houston Houston Texas USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2026 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
YBYossi Bart
Yossi Bart
ZDZakaria Doughan
Zakaria Doughan
LDLaura Diab
Laura Diab
AMAhmed Salaheldin Zaki Moustafa
Ahmed Salaheldin Zaki Moustafa
BSBaha M. Sibai
Baha M. Sibai

3 August 2026 in Pregnancy
Verified
Journal Article
Open access
PDF file
ZDZakaria Doughan
Zakaria Doughan
YBYossi Bart
Yossi Bart
JHJoe Haydamous
Joe Haydamous
LDLaura Diab
Laura Diab
Sara GiulianoSara Giuliano
Sara Giuliano
BSBaha M. Sibai
Baha M. Sibai
Background: Expectant management of early‐onset preeclampsia with severe features (<34 weeks’ gestation) requires close maternal surveillance. Although serial testing is routinely performed, recommendations regarding testing frequency vary across professional societies and the clinical utility and financial impact of frequent testing during expectant management remain uncertain. Objective: To describe the role of serial blood tests in guiding delivery decision‐making in preeclampsia with severe features, and to assess the health costs of these serial blood tests. Study Design: A retrospective cohort study of singleton pregnancies diagnosed with preeclampsia with severe features between 23 and 33 weeks at a level IV academic maternity center. Patients with contraindications to expectant management were excluded. Delivery indications were categorized by the contribution of blood test abnormalities: no abnormal blood tests contributing to delivery; blood test abnormalities detected once the decision for delivery was made, but not indication for delivery; and blood test abnormalities as the indication for delivery. Primary outcome was delivery prompted by abnormal blood test findings. Secondary outcomes included charges associated with serial testing. Data analysis included percent with 95% confidence intervals (CIs) or median with interquartile ranges (IQRs). Results: A total of 370 patients met inclusion criteria. Only five (1.4%; 95% CI, 0.4–3.1) had abnormal blood test values (transaminitis and/or thrombocytopenia) prompting delivery decisions, all appearing within 4 days of admission. Abnormal blood testing was not an indication for delivery for most patients ( N = 325; 87.8%; 95% CI, 84.1–91.0). For 40 patients (10.8%; 95% CI, 7.8–14.4), blood test abnormalities were detected after decision for delivery was made. The median number of blood tests per patient was 10 (IQR 6–14), and blood testing charge per patient was $5030 (IQR 3018–7042). The total charge for blood testing was $2.176 million over the study period. Conclusion: Among 370 patients with early‐onset preeclampsia with severe features managed expectantly, only 1% of the cohort had blood test abnormalities as the sole indication for delivery. All other patients were delivered either because of maternal‐fetal indications or developed blood test abnormalities occurring in association with other indications for delivery. Finally, serial blood testing in this setting resulted in total charges of $2.176 million over 9 years. Based on this large cohort, there is a need to reconsider the frequency of blood testing in the absence of new‐onset symptoms or worsening severe features.